Recent News

• 06.11.2025 - bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas’ Leadership Board
• 06.03.2025 - bioAffinity Technologies Works With Cardinal Health™ OptiFreight® Logistics to Help Meet Demand for CyPath® Lung
• 05.28.2025 - bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics
• 05.20.2025 - bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer
• 05.15.2025 - bioAffinity Technologies Reports First Quarter 2025 Results
• 05.08.2025 - Independent White Paper Highlights Real-World Impact of bioAffinity Technologies’ CyPath® Lung in Diagnosing Early-Stage Lung Cancer

Recent Filings

• 06.02.2025 - ARS Annual Report to Security Holders
• 06.02.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 06.02.2025 - DEF 14A Other definitive proxy statements
• 05.30.2025 - 8-K Current report
• 05.27.2025 - 8-K Current report
• 05.27.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 05.23.2025 - PRER14A Preliminary Proxy Soliciting materials
• 05.19.2025 - 8-K Current report
• 05.15.2025 - 8-K Current report
• 05.15.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]